Small Cap Biotech with Large September FDA Action Date

Allos Therapeutics, Inc (biotech ticker: ALTH)
Drug: Pralatrexate is intended as a treatment for T-cell lymphoma that has recurred or not responded to other drugs.

FDA Committee to vote September 2 2009
FDA action Date: September 24th 2009

Salix Pharmaceuticals, Ltd. (biotech ticker:SLXP)
Drug: Metozolv (Metoclopramide) fast–dissolving formulation of metoclopramide, acquisition from Wilmington Pharmaceuticals in September 2007. an Oral disintegrating tablet (ODT) formulation of metoclopramide, for the treatment of short–term therapy (4–12 weeks) for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis

FDA action date: September 11th 2009

ISTA Pharmaceuticals, Inc. (biotech ticker: ISTA)
Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5% as an eye drop treatment for ocular itching associated with allergic conjunctivitis. June 26 2009; FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee recommended the approval of Bepreve 7-0 in favor.

FDA action date: September 12th 2009